FAAH and Alzheimer disease: Since the monocytes expressed remarkable levels of FAAH, which were even higher in AD patients and indicated their higher ability to metabolically inactivate endogenous eCBs, we next sought to investigate the possibility of pharmacologically inhibiting enzyme activity in the monocytes of AD patients with URB597, and to evaluate the inflammatory responses following LPS activation.